Filing Flows › Monte Rosa Therapeutics (GLUE) › R&D spending
Monte Rosa Therapeutics (GLUE) R&D spending by quarter
Monte Rosa Therapeutics' R&D spending was $45.4M in Q3 2026 (third quarter 2026), -5% from Q2 2026. Over the last 7 quarters it ranged from $30.7M (Q2 2025) to $48.0M (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $45.4M | -5% | +24% |
| Q2 2026 | $48.0M | +9% | +56% |
| Q1 2026 | $44.1M | +5% | +37% |
| Q4 2025 | $42.0M | +14% | — |
| Q3 2025 | $36.7M | +20% | — |
| Q2 2025 | $30.7M | -5% | — |
| Q1 2025 | $32.2M | — | — |
Q3 2026 at a glance
Monte Rosa Therapeutics, Q3 2026: revenue $54.4M (+326% year over year), operating margin -3.6%, net earnings $3.1M, operating cash flow −$41.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Monte Rosa Therapeutics' R&D spending?
Monte Rosa Therapeutics' R&D spending was $45.4M in Q3 2026 (third quarter 2026), -5% from Q2 2026.
How has Monte Rosa Therapeutics' R&D spending changed?
Over the last 7 quarters it ranged from $30.7M (Q2 2025) to $48.0M (Q2 2026).
Q3 2026 results → · How Monte Rosa Therapeutics makes money →